Physician profile
Morgan T Everett
NPI 1669090932
$5,162.89
in general payments reported to CMS, 2019-2025
33 companies · $1,343 in 2025
The $1,343 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $16.33 · 2022: $1,347 · 2023: $923 · 2024: $1,534 · 2025: $1,343.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,798 · Education: $2.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,798.06 |
| Education | $2.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $873.94 | 2022-2025 | Lifevest |
| Edwards Lifesciences Corporation | $779.47 | 2024-2025 | Sapien 3 Ultra Resilia |
| Novartis Pharmaceuticals Corporation | $740.28 | 2022-2025 | |
| Pfizer INC. | $539.81 | 2022-2025 | |
| Boston Scientific Corporation | $295.16 | 2023-2025 | Watchman Flx, Bodyguardian, Watchman Access System |
| E.R. Squibb & Sons, L.L.C. | $233.43 | 2022-2025 | Camzyos, Eliquis |
| Amgen INC. | $220.16 | 2022-2024 | Repatha |
| Abiomed | $187.32 | 2022-2024 | Impella |
| Merck Sharp & Dohme LLC | $120.45 | 2022-2025 | Verquvo |
| Amarin Pharma, INC. | $117.25 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $114.54 | 2023-2025 | Wainua, Farxiga |
| Scpharmaceuticals INC. | $104.91 | 2023-2024 | |
| Janssen Pharmaceuticals, INC | $92.57 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $81.52 | 2022-2023 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $79.72 | 2022-2023 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $70.68 | 2024-2025 | Inspire |
| Philips North America LLC | $68.00 | 2025 | Ecc Solutions, Ambulatory Monitoring & Diagnostics Undivided |
| Sanofi-Aventis U.S. LLC | $57.61 | 2024 | |
| Alnylam Pharmaceuticals INC. | $54.93 | 2022-2025 | Amvuttra |
| Esperion Therapeutics, INC. | $48.11 | 2024 | Nexletol |
| Kiniksa Pharmaceuticals, LTD. | $40.58 | 2023 | Arcalyst |
| Atricure, INC. | $35.47 | 2024 | |
| Cvrx, INC. | $33.66 | 2024 | Barostim Neo System |
| Medtronic, INC. | $23.44 | 2022 | |
| Daiichi Sankyo INC. | $22.65 | 2022 | |
| Kiniksa Pharmaceuticals International, Plc | $22.39 | 2024 | Arcalyst |
| Actelion Pharmaceuticals US, INC. | $19.64 | 2023 | Opsumit, Uptravi |
| Astellas Pharma US INC | $18.46 | 2022 | |
| Inogen, INC. | $15.82 | 2022 | |
| Altathera Pharmaceuticals LLC | $15.05 | 2025 | Sotalol Hydrochloride |
| Convatec INC. | $14.04 | 2024 | |
| Kowa Pharmaceuticals America, INC. | $12.10 | 2022 | |
| Vivaquant INC, Dba Rhythm Express | $9.73 | 2025 | Rhythm Express |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Morgan Everett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.